ICUCriticalCommon
Sepsis & Septic Shock
Life-threatening organ dysfunction from infection. Every hour of antibiotic delay = ~7% more mortality. Diagnose fast, culture fast, treat fast. Source control is as important as antibiotics.
๐ Overview
Sepsis-3 Definitions (Singer, JAMA 2016)
Sepsis: Life-threatening organ dysfunction caused by a dysregulated host response to infection. Operationally defined as SOFA score increase โฅ 2 from baseline in a patient with suspected infection.
Septic Shock: Sepsis + vasopressor requirement to maintain MAP โฅ 65 mmHg + serum lactate > 2 mmol/L despite adequate fluid resuscitation. In-hospital mortality > 40%.
Septic Shock: Sepsis + vasopressor requirement to maintain MAP โฅ 65 mmHg + serum lactate > 2 mmol/L despite adequate fluid resuscitation. In-hospital mortality > 40%.
qSOFA (bedside screen -1 point each): Altered mentation (GCS < 15) | RR โฅ 22 | SBP โค 100. Score โฅ 2 = high risk โ triggers full SOFA + ICU evaluation. qSOFA is a screen, NOT a definition.
โ ๏ธ SSC 2026: qSOFA has poor sensitivity -misses too many septic patients. NEWS/MEWS now recommended as primary screening tools.
โ ๏ธ SSC 2026: qSOFA has poor sensitivity -misses too many septic patients. NEWS/MEWS now recommended as primary screening tools.
NEWS / MEWS Calculators -SSC 2026 recommended sepsis screening tools. NEWS โฅ7 = emergency. MEWS โฅ5 = urgent review.
๐งฎ Calculate NEWS / MEWS โ
SIRS Criteria (historical -Bone, Chest 1992): Infection + โฅ 2 of: Temp > 38ยฐC or < 36ยฐC | HR > 90 | RR > 20 or PaCOโ < 32 | WBC > 12,000 or < 4,000 or > 10% bands.
Replaced by Sepsis-3 (2016) due to poor specificity -SIRS is present in most hospitalized patients Sepsis-3, 2016 regardless of infection. Still used as a triage trigger in some institutions given its high sensitivity.
Replaced by Sepsis-3 (2016) due to poor specificity -SIRS is present in most hospitalized patients Sepsis-3, 2016 regardless of infection. Still used as a triage trigger in some institutions given its high sensitivity.
๐ด SSC 2026 Guidelines (March 2026) -Key Changes from 2021:
| Domain | 2021 SSC | 2026 SSC Update |
|---|---|---|
| Screening | qSOFA suggested outside ICU | NEWS/NEWS2/MEWS/SIRS now recommended OVER qSOFA. qSOFA has poor sensitivity -should not be sole screening tool. |
| Fluids | 30 mL/kg crystalloid within 3h. No preference NS vs balanced. | 30 mL/kg still suggested. Balanced crystalloids now suggested over 0.9% saline (except TBI). New: fluid removal after resuscitation now addressed. |
| Vasopressors | Start via central line. NE first-line (strong). | Peripheral vasopressor start now OK -don't delay for central access. NE still first-line but downgraded to conditional ("suggest"). New: MAP 60-65 for adults โฅ 65 years. |
| Steroids | Suggested if ongoing vasopressor need (reversed 2016 stance against routine steroids) | Maintained from 2021. Hydrocortisone 200 mg/day for septic shock with ongoing vasopressor requirement. No specific wait time mandated (trial enrollment used โฅ 4h). |
| Antibiotics | Within 1h of recognition | Refined: 1 hour for septic shock, 3 hours for sepsis without shock. New: antibiotic optimization & prehospital antibiotics may reduce mortality (OR 0.58). |
| Beta-lactam dosing | Not addressed | Recommend (strong) prolonged infusion of beta-lactams for maintenance after loading dose. Improves time-dependent killing. |
| Anaerobic coverage | Routine empiric pip-tazo / metronidazole as part of broad-spectrum cover | Stop reflexively adding anaerobic coverage. Chanderraj, 2024 showed empiric anti-anaerobic agents in critically ill patients without an anaerobic source โ mortality, C. diff, and VRE. New default empiric: Vanc + Cefepime. Add Zosyn / metronidazole only for clear anaerobic sources (intra-abdominal, aspiration w/ abscess, nec fasc, pelvic, bite wound). |
Pathophysiology
Infection triggers innate immune activation โ cytokine storm (TNF-ฮฑ, IL-1, IL-6) โ endothelial dysfunction โ vasodilation + capillary leak โ distributive shock. Simultaneously, microvascular thrombosis + impaired oxygen utilization โ end-organ ischemia even when MAP is maintained. This explains why restoring BP alone is insufficient -tissue perfusion and oxygen delivery must be optimized.
Sources MOST โ LEAST COMMON
| Source | Frequency | Typical pathogens |
|---|---|---|
| Pulmonary (pneumonia) | ~40โ50% | S. pneumoniae, K. pneumoniae, P. aeruginosa, MRSA, influenza, COVID-19 |
| Genitourinary | ~20โ25% | E. coli, Klebsiella, Proteus, enterococci |
| Intra-abdominal | ~15โ20% | Polymicrobial gram-negatives + anaerobes (B. fragilis); E. coli, enterococci. Sources: cholangitis, perforation, diverticulitis, abscess, ischemic bowel |
| Skin / soft tissue | ~5โ10% | S. aureus (incl. MRSA), Group A strep, Clostridium. Includes necrotizing fasciitis, cellulitis, infected wounds, decubitus ulcers |
| Catheter / line / device | ~5% | CoNS, S. aureus, Candida, gram-negatives. CLABSI, infected hardware (pacemaker, prosthetic joint, VP shunt) |
| CNS, endocarditis, other | < 5% | Variable. CNS: S. pneumoniae, N. meningitidis, Listeria (elderly/immunocompromised). Endocarditis: S. aureus, viridans strep, enterococci. Consider early in sepsis with no clear source, especially with fever + AMS or new murmur |
| No source identified | ~10โ15% | Empiric broad-spectrum coverage; reassess daily. Higher in immunocompromised (neutropenic fever, post-transplant). Consider occult abscess, fungal, viral, atypical organisms |
Source control is as important as antibiotics. SSC 2026 emphasizes anatomic source control (drain abscesses, remove infected lines, debride necrotic tissue, decompress obstructed urinary tract) within 6โ12 hours of recognition. Antibiotics alone fail without source control.
Presentation
- Fever > 38.3ยฐC OR hypothermia < 36ยฐC (hypothermia = worse prognosis)
- Tachycardia, tachypnea
- Hypotension, warm/flushed skin (early distributive), later cold/mottled
- Altered mental status (confusion, agitation, lethargy)
- Decreased urine output (< 0.5 mL/kg/hr)
- Elevated lactate (tissue hypoperfusion marker)
Don't Be Fooled: Elderly, immunocompromised (transplant, chemotherapy), and patients on chronic steroids may present with NO fever, minimal leukocytosis, and normal HR. Hypothermia and leukopenia in sepsis = very bad prognostic signs. Think sepsis in any elderly patient with AMS + unexplained hypotension.
๐งช Workup & Diagnosis
Sepsis Bundle SSC, 2026
Septic shock: ALL within 1 hour. Sepsis without shock: antibiotics within 3 hours. (SSC 2026 now distinguishes timing by severity -previously 1h for all sepsis.)
- Measure serum lactate (repeat if initial > 2 mmol/L to confirm clearance)
- Blood cultures ร 2 sets from 2 separate sites -before antibiotics, but do not delay antibiotics > 45 min waiting for cultures
- Broad-spectrum antibiotics administered IV, 1h for septic shock, 3h for sepsis without shock (SSC 2026)
- 30 mL/kg balanced crystalloid (LR or PlasmaLyte) bolus if MAP < 65 mmHg OR lactate โฅ 4 mmol/L (SSC 2026 suggests balanced over 0.9% saline, except TBI)
- Vasopressors if MAP < 65 despite fluid resuscitation โ target MAP โฅ 65
Laboratory Workup
Mandatory
- Lactate -venous or arterial; most critical early test; > 4 = cryptic shock regardless of BP
- Blood cultures ร 2 peripheral sets (before antibiotics)
- BMP -creatinine (AKI), glucose, bicarb (metabolic acidosis)
- CBC with differential (leukocytosis, left shift, or leukopenia)
- Procalcitonin -helps guide antibiotic duration (de-escalation at < 0.25)
Targeted by Suspected Source
- UA + urine culture (UTI/urosepsis -2nd most common source)
- Sputum Gram stain + culture, respiratory panel (pneumonia -most common source)
- LFTs, lipase, RUQ ultrasound (abdominal source)
- Coagulation panel (PT/INR, PTT, fibrinogen) -if DIC suspected
- LP (cell count, protein, glucose, Gram stain, culture) if CNS source
- C. diff if recent antibiotics + diarrhea
Imaging
- Bedside echo -cardiac function, IVC collapsibility (volume status), wall motion, pericardial effusion (fastest, most actionable)
- CXR -portable if unstable; pneumonia, pulmonary edema, effusion
- RUQ ultrasound -gallbladder, biliary dilation (cholangitis)
- CT abdomen/pelvis with contrast -abdominal source, abscess (do not delay abx for CT)
- CT head -if AMS, meningismus, focal neuro deficit (LP after if no mass lesion)
Lactate Interpretation
| Lactate Level | Category | Action |
|---|---|---|
| < 2 mmol/L | Normal | Standard care; monitor if clinical concern |
| 2โ4 mmol/L | Elevated -sepsis | Aggressive resuscitation; repeat lactate in 2h |
| โฅ 4 mmol/L | Cryptic shock | Mandatory aggressive resuscitation: 30 mL/kg balanced crystalloid, ICU evaluation, source control, repeat lactate q2h. Vasopressors if MAP < 65 after fluids (per SSC 2026, not all cryptic shock requires immediate pressors if BP responds). |
Lactate Clearance: Target โฅ 10% clearance per 2 hours. Failure to clear lactate despite resuscitation = inadequate source control, occult bleeding, or mitochondrial dysfunction. Persistently elevated lactate = very poor prognosis.
๐จ Management
Resuscitation Strategy
0โ15 min -Recognition & Stabilisation
ABCs. Two large-bore IVs. Cardiac monitor. Oโ. Call for help.
If shock criteria met (MAP < 65, lactate โฅ 4, AMS): activate ICU consult now -not after labs, not after imaging. Bedside echo to exclude obstructive shock (PE, tamponade) and assess LV function.
If shock criteria met (MAP < 65, lactate โฅ 4, AMS): activate ICU consult now -not after labs, not after imaging. Bedside echo to exclude obstructive shock (PE, tamponade) and assess LV function.
0โ30 min -Cultures then Antibiotics (in that order, fast)
Blood cultures ร 2 โ broad-spectrum antibiotics within 1 hour. Every hour of delay in septic shock increases mortality ~7%. Narrow based on culture results at 48โ72h.
| Drug | Dose | Bugs Covered | โ ๏ธ Side Effects | When to Use |
|---|---|---|---|---|
| Piperacillin-tazobactam (Zosyn) | 3.375g IV q6h (or 4.5g q8h extended infusion over 4h) | Gram-positives: Strep, MSSA (not MRSA) Gram-negatives: E. coli, Klebsiella, Proteus, Pseudomonas, Enterobacter Anaerobes: Bacteroides, Fusobacterium | โ ๏ธ โ AKI when paired with vancomycin ACORN, 2024 (use cefepime + vanc as default empiric unless anaerobic source). C. diff (higher than cefepime, broad anaerobic kill). Hypokalemia (common, often missed, check daily BMP; mechanism = non-reabsorbable anion in distal tubule). Thrombocytopenia & neutropenia with courses > 7โ14 days. Rash; DRESS (rare); cross-reactivity with severe PCN allergy. Transaminitis; cholestasis with prolonged infusion. False-positive serum galactomannan (critical in heme/onc aspergillus screening). Drug fever. Seizures in renal failure (rare). Diarrhea (non-C. diff). | Reserve for clear anaerobic source (intra-abdominal, aspiration w/ abscess, nec fasc, pelvic, bite wound). No longer the default empiric in 2026, Chanderraj, 2024 showed empiric anti-anaerobic agents without an anaerobic indication โ mortality, C. diff, and VRE. |
| Cefepime (Maxipime) | 2g IV q8h | Gram-positives: Strep, MSSA (not MRSA) Gram-negatives: E. coli, Klebsiella, Pseudomonas, Enterobacter, Serratia, Citrobacter No anaerobes | โ ๏ธ Cefepime-induced neurotoxicity (CIN), encephalopathy, confusion, myoclonus, asterixis, tremor, non-convulsive status epilepticus. Esp. renal failure, elderly, sepsis. Often misdiagnosed as ICU delirium; EEG shows triphasic waves or generalized periodic discharges. Resolves with discontinuation ยฑ HD. Dose-adjust aggressively for CrCl. Overt seizures (part of spectrum). C. diff. Rash; hypersensitivity (PCN cross-reactivity ~1โ3%, safe in non-severe PCN allergy). Thrombocytopenia, eosinophilia, positive Coombs (rare AIHA). Transaminitis. Drug fever; infusion-site phlebitis. Candidiasis / thrush with prolonged use. | New 2026 default empiric (paired with vanc). Covers Pseudomonas + GNR without anaerobic spectrum. โ AKI vs pip-tazo+vanc. Add metronidazole only if a true anaerobic source is identified. |
| Meropenem (Merrem) | 1g IV q8h | Gram-positives: Strep, MSSA (not MRSA) Gram-negatives: E. coli, Klebsiella, Pseudomonas, Enterobacter, ESBL-producers, Acinetobacter Anaerobes: Bacteroides | โ ๏ธ Seizures (esp. renal failure, CNS lesion, elderly, high dose, lower risk than imipenem; always dose-adjust for CrCl). โ valproic acid 50โ90% in 24โ48h โ breakthrough seizures/status epilepticus (AVOID combo, dose-escalating VPA does NOT rescue; bridge to levetiracetam). C. diff, diarrhea, nausea. Rash / hypersensitivity (PCN cross-reactivity ~1%, safe in non-severe PCN allergy). Thrombocytosis, eosinophilia, positive Coombs (rare AIHA); transaminitis. VRE + Candida superinfection with prolonged courses. Encephalopathy/myoclonus in renal failure. | Use if: prior ESBL/MDR organism, recent hospitalization + IV abx within 90 days, high local resistance, failed pip-tazo. Broadest gram-negative coverage. |
| Vancomycin (Vancocin) | 15โ20 mg/kg IV q8โ12h (AUC/MIC target 400โ600) | Gram-positives only: MRSA, MSSA, Strep, Enterococcus (not VRE) No gram-negatives. No anaerobes. | โ ๏ธ Nephrotoxicity / AKI (dose- and duration-dependent; worse with pip-tazo ACORN, 2024; AUC/MIC 400โ600 guided dosing โ risk vs trough-only). Vancomycin flushing syndrome (formerly "Red Man", histamine release, NOT IgE allergy; infuse over โฅ 1h, pre-treat with antihistamine if recurrent). Ototoxicity (dose/duration; additive with loops + aminoglycosides). DRESS, SJS/TEN (rare). Linear IgA bullous dermatosis. Neutropenia + thrombocytopenia with courses > 7โ14 days. Drug fever. Phlebitis, prefer central line for prolonged courses. | Add for MRSA coverage -any sepsis with: prior MRSA, IVDU, skin/soft tissue source, healthcare exposure, HD catheter. Pair with pip-tazo, cefepime, or meropenem. |
| Linezolid (Zyvox) | 600 mg IV/PO q12h | Gram-positives only: MRSA, VRE, Strep, Enterococcus No gram-negatives. No anaerobes. | โ ๏ธ Thrombocytopenia (courses > 7โ14d, monitor CBC weekly; most common dose-limiting toxicity). Serotonin syndrome (weak reversible MAOi, avoid SSRIs, SNRIs, tramadol, meperidine, TCAs; ideally 2-week washout. Classic inpatient pimp trap). Peripheral neuropathy + optic neuritis (courses > 28d, may be irreversible; discontinue at first sign). Myelosuppression / pancytopenia (marrow suppression, > 14d). Lactic acidosis (mitochondrial protein synthesis inhibition, prolonged use, often > 28d). Tyramine reaction (avoid aged cheese, cured meats, wine, MAOi effect). Hypoglycemia in diabetics on sulfonylureas/insulin. Headache, nausea, diarrhea, rash. | Alternative to vanc if: CKD/AKI (no renal adjustment), VRE suspected, MRSA pneumonia (superior lung penetration), no IV access (100% PO bioavailability). |
| Metronidazole (Flagyl) | 500 mg IV q8h | Anaerobes: Bacteroides fragilis, Clostridium, Fusobacterium, Prevotella Protozoa: C. diff (PO), Giardia, Entamoeba | โ ๏ธ Disulfiram-like reaction with alcohol (flushing, tachycardia, nausea, vomiting, counsel: NO alcohol during + 72h after. Applies to mouthwash, cough syrup, IV meds in propylene glycol). Peripheral neuropathy (dose- and duration-related, distal axonal, courses > 4โ6 weeks; may be irreversible). CNS toxicity, encephalopathy, cerebellar syndrome (ataxia, dysarthria, nystagmus), seizures. MRI: symmetric cerebellar dentate / corpus callosum splenium lesions; reversible with discontinuation. Metallic taste + nausea (very common, adherence issue). Warfarin INR โ (CYP2C9 inhibition, recheck INR at 48โ72h; anticipate dose reduction). Lithium toxicity. Reversible leukopenia. Optic neuropathy (rare). Aseptic meningitis (very rare). | Add to cefepime or meropenem when anaerobic coverage needed (intra-abdominal, abscess, aspiration with empyema). Not needed with pip-tazo (already covers anaerobes). |
Key principle (2026): Default empiric is Vanc + Cefepime, covers MRSA + Pseudomonas + GNR without unnecessary anaerobic spectrum. Add Zosyn or metronidazole only when there's a clear anaerobic source (intra-abdominal, aspiration w/ abscess/empyema, nec fasc, pelvic, bite wound).
Fluid Resuscitation
30 mL/kg balanced crystalloid (LR or PlasmaLyte preferred over NS) SMART, 2018 SALT-ED, 2018 if MAP < 65 or lactate โฅ 4. Early aggressive resuscitation is key Rivers EGDT, 2001 -though the specific EGDT protocol (CVP, ScvO2 targets) was later shown unnecessary by ProCESS, 2014.
After initial bolus: reassess after each 500 mL. Check JVP, lung auscultation, passive leg raise response. Do not reflexively give more fluids if no hemodynamic response -start vasopressors. Fluid overload in sepsis = worse outcomes. CLOVERS, 2023 showed no benefit to liberal fluid strategy, supporting a conservative approach. Use crystalloids over colloids -CRISTAL, 2013 found no 28-day mortality difference between colloids and crystalloids. Notably, FEAST, 2011 demonstrated that fluid boluses increased mortality in febrile children (resource-limited setting), underscoring the importance of judicious fluid use.
After initial bolus: reassess after each 500 mL. Check JVP, lung auscultation, passive leg raise response. Do not reflexively give more fluids if no hemodynamic response -start vasopressors. Fluid overload in sepsis = worse outcomes. CLOVERS, 2023 showed no benefit to liberal fluid strategy, supporting a conservative approach. Use crystalloids over colloids -CRISTAL, 2013 found no 28-day mortality difference between colloids and crystalloids. Notably, FEAST, 2011 demonstrated that fluid boluses increased mortality in febrile children (resource-limited setting), underscoring the importance of judicious fluid use.
๐ Updated Practice (SSC 2026): Balanced crystalloids (LR/PlasmaLyte) now suggested over 0.9% saline (except TBI -use NS). 30 mL/kg remains suggested but with greater emphasis on individualization. CLOVERS, 2023 showed no difference between restrictive (~1.8L) and liberal (~3.8L) strategies. New in 2026: fluid removal after resuscitation is now addressed -de-resuscitate once stabilized. Fluid overload kills -reassess after each bolus.
Vasopressors -MAP Target โฅ 65
Norepinephrine first-line (start 0.01โ0.05 mcg/kg/min, titrate to max ~3 mcg/kg/min) SOAP II, 2010 -ฮฑโ > ฮฒโ, increases MAP without excessive HR.
Add vasopressin 0.03 units/min (fixed dose, no titration) when NE reaches 0.25โ0.5 mcg/kg/min (spares NE, possibly reduces mortality) VASST 2008.
Add epinephrine for refractory shock. Use dobutamine (2โ20 mcg/kg/min) only if MAP adequate but persistent signs of low CO (cold extremities, rising lactate, low ScvOโ).
Hydrocortisone 200 mg/day IV (50 mg q6h or continuous) for septic shock with ongoing vasopressor requirement (SSC 2021/2026 -conditional recommendation). Shortens shock duration. ADRENAL 2018; APROCCHSS 2018 CORTICUS, 2008.
Add vasopressin 0.03 units/min (fixed dose, no titration) when NE reaches 0.25โ0.5 mcg/kg/min (spares NE, possibly reduces mortality) VASST 2008.
Add epinephrine for refractory shock. Use dobutamine (2โ20 mcg/kg/min) only if MAP adequate but persistent signs of low CO (cold extremities, rising lactate, low ScvOโ).
Hydrocortisone 200 mg/day IV (50 mg q6h or continuous) for septic shock with ongoing vasopressor requirement (SSC 2021/2026 -conditional recommendation). Shortens shock duration. ADRENAL 2018; APROCCHSS 2018 CORTICUS, 2008.
๐ Updated Practice (SSC 2026): Peripheral vasopressor start is now OK -don't delay pressors waiting for central access. Norepinephrine remains first-line but downgraded from "recommend" to "suggest" (still first-line, weaker strength). Vasopressin second-line (0.03 units/min, fixed). Dopamine and "renal-dose dopamine" are DEBUNKED. New in 2026: for adults โฅ 65, suggest initial MAP 60-65 mmHg over higher targets. Prolonged beta-lactam infusion now recommended (strong) for maintenance dosing after loading dose.
Source Control
Identify and eliminate the source of infection -as important as antibiotics.
Drain abscess (IR-guided or surgical). Remove infected IV lines (replace in new site). Decompress biliary obstruction (ERCP or percutaneous). Surgical consult for perforated viscus, necrotizing fasciitis, infected prosthetic. Time to source control should be < 6โ12 hours for drainage procedures.
Drain abscess (IR-guided or surgical). Remove infected IV lines (replace in new site). Decompress biliary obstruction (ERCP or percutaneous). Surgical consult for perforated viscus, necrotizing fasciitis, infected prosthetic. Time to source control should be < 6โ12 hours for drainage procedures.
ICU-Level Bundles
Ventilation: Lung-protective if intubated (TV 6 mL/kg IBW, Pplat โค 30).
Glucose: Target 140โ180 mg/dL with insulin infusion NICE-SUGAR, 2009. Avoid hypoglycemia.
DVT prophylaxis: Enoxaparin (or UFH if CrCl < 30) + SCDs.
Stress ulcer prophylaxis: IV PPI or H2-blocker if high-risk (mechanically ventilated > 48h, coagulopathy, history of GI bleed, TBI, burns > 35% BSA). Not all ICU patients need it -SUP-ICU, 2018: no mortality benefit from routine prophylaxis; weigh risk of C. difficile and nosocomial pneumonia.
Nutrition: Early enteral nutrition within 24โ48h. Enteral is preferred over parenteral -NUTRIREA-2, 2018 and CALORIES, 2014 showed no mortality difference between parenteral and enteral, but enteral maintains gut integrity.
Antibiotic de-escalation: Reassess at 48โ72h based on cultures + clinical trajectory. Target 5โ7 days total if good source control and clinical improvement. Use procalcitonin to guide stopping PRORATA 2010.
Glucose: Target 140โ180 mg/dL with insulin infusion NICE-SUGAR, 2009. Avoid hypoglycemia.
DVT prophylaxis: Enoxaparin (or UFH if CrCl < 30) + SCDs.
Stress ulcer prophylaxis: IV PPI or H2-blocker if high-risk (mechanically ventilated > 48h, coagulopathy, history of GI bleed, TBI, burns > 35% BSA). Not all ICU patients need it -SUP-ICU, 2018: no mortality benefit from routine prophylaxis; weigh risk of C. difficile and nosocomial pneumonia.
Nutrition: Early enteral nutrition within 24โ48h. Enteral is preferred over parenteral -NUTRIREA-2, 2018 and CALORIES, 2014 showed no mortality difference between parenteral and enteral, but enteral maintains gut integrity.
Antibiotic de-escalation: Reassess at 48โ72h based on cultures + clinical trajectory. Target 5โ7 days total if good source control and clinical improvement. Use procalcitonin to guide stopping PRORATA 2010.
Resuscitation Targets
| Parameter | Target | Notes |
|---|---|---|
| MAP | โฅ 65 mmHg (60-65 if age โฅ 65) | Higher (โฅ 75) in chronic hypertension or AKI. SSC 2026: lower target 60-65 for older adults spares vasopressor exposure. |
| Lactate | Clearance โฅ 10% per 2h | Target < 2 mmol/L; failure to clear = reassess |
| UOP | โฅ 0.5 mL/kg/hr | Oliguria = inadequate perfusion or AKI |
| ScvOโ | โฅ 70% | Low = high Oโ extraction โ low CO or anemia |
| Glucose | 140โ180 mg/dL | Avoid hypoglycemia -check q1โ2h |
| Hgb | โฅ 7โ9 g/dL | Transfuse if Hgb < 7 (or < 8 if cardiac ischemia) TRICC, 1999 |
๐ Medications & Doses
Empiric Antibiotic Selection
๐ SSC 2026 + Chanderraj, 2024, pick empiric by source, not by reflex. Two principles drive every choice below:
- No anaerobic source โ no anti-anaerobic agent. Routine empiric pip-tazo, metronidazole, or clindamycin in critically ill patients without an anaerobic indication is associated with higher mortality, C. difficile, and VRE. Chanderraj, 2024
| Clinical Scenario | Empiric Regimen | Notes |
|---|---|---|
| Sepsis, no clear source (default while workup pending) | Cefepime (Maxipime) 2g IV q8h (Pseudomonas, E. coli, Klebsiella, Enterobacter, MSSA) + Vancomycin (Vancocin) 25โ30 mg/kg loading (MRSA, Strep, Enterococcus) | New 2026 default. Covers MRSA + Pseudomonas + GNR without unnecessary anaerobic coverage. Use this instead of Vanc + Zosyn unless an anaerobic source is identified. |
| CAP (community-acquired pneumonia) Pulmonary source = ~40โ50% of sepsis | Ceftriaxone (Rocephin) 1โ2g IV daily + Azithromycin (Zithromax) 500 mg IV/PO | Typical organisms (S. pneumoniae, H. influenzae) + atypicals (Mycoplasma, Legionella). Add vanc if MRSA risk (post-influenza, cavitary, prior MRSA). Levofloxacin monotherapy is an alternative. |
| Severe CAP + sepsis / HAP / VAP | Cefepime (Maxipime) 2g IV q8h + Vancomycin (Vancocin) | Pseudomonas + MRSA coverage. Cefepime preferred over Zosyn (2026), pneumonia is not an anaerobic source unless aspiration with abscess or empyema. |
| Urosepsis (community-acquired) GU source = ~20โ25% of sepsis | Ceftriaxone (Rocephin) 1โ2g IV daily | E. coli is #1 (~80%). Urinary tract is not an anaerobic source. Adjust by Gram stain + culture. Add ampicillin if Enterococcus on Gram stain. Cefepime if Pseudomonas risk (recurrent UTI, indwelling catheter, prior Pseudomonas). |
| Biliary / intra-abdominal source Abdominal source = ~15โ20% of sepsis (perforation, peritonitis, cholangitis, diverticulitis, abscess) | Pip-tazo (Zosyn) 4.5g IV q6h OR Ceftriaxone + Metronidazole (Flagyl) 500 mg IV q8h | True anaerobic source. Anaerobic coverage is appropriate here. Urgent source control (ERCP, IR drainage, surgery) is as critical as antibiotics. |
| SBP (cirrhosis + ascites) | Ceftriaxone (Rocephin) 2g IV daily | SBP is monomicrobial GNR (E. coli, Klebsiella), does NOT need anaerobic coverage. If healthcare-associated SBP or recent broad abx: cefepime or meropenem. |
| Cellulitis (admitted, severe, non-necrotizing) Skin/soft tissue source = ~5โ10% of sepsis | Vancomycin (Vancocin) (MRSA) + Cefepime only if GNR risk or unstable | Not an anaerobic infection. Most non-necrotizing cellulitis is Group A strep + S. aureus. Vanc alone is often sufficient. Skip Zosyn unless polymicrobial features. |
| Aspiration pneumonia with lung abscess, empyema, or witnessed large-volume aspiration | Ampicillin-sulbactam (Unasyn) 3g IV q6h OR Pip-tazo (Zosyn) 4.5g IV q6h | Routine "aspiration" CAP does NOT need anaerobic coverage. Reserve for clear anaerobic features: abscess, empyema, putrid sputum, severe dental disease, witnessed aspiration of gastric contents. |
| Neutropenic fever (ANC < 500) | Cefepime (Maxipime) 2g IV q8h ยฑ Vancomycin | Cefepime monotherapy is the standard. Add vanc only for: hemodynamic instability, line infection, skin/soft tissue source, severe mucositis, or known MRSA colonization. Add micafungin at day 4โ5 if persistent fever. |
| Suspected meningitis CNS source = < 5% of sepsis | Ceftriaxone (Rocephin) 2g IV q12h + Vancomycin + Dexamethasone (Decadron) 0.15 mg/kg IV q6h ร 4d | Dex before or with first abx dose. Add ampicillin 2g IV q4h for Listeria if > 50yo, immunocompromised, or pregnant. Add acyclovir if HSV encephalitis suspected. |
| Necrotizing fasciitis | Vancomycin + Pip-tazo (Zosyn) 4.5g IV q6h + Clindamycin (Cleocin) 900 mg IV q8h | Polymicrobial soft tissue โ anaerobes appropriate. Clindamycin = toxin suppression (50S inhibition), not for coverage. Surgical emergency, debridement ASAP. |
| Suspected fungal sepsis | Micafungin (Mycamine) 100 mg IV daily OR Fluconazole (Diflucan) 800 mg IV load โ 400 mg daily | Risk factors: TPN, prior broad-spectrum abx, abdominal surgery, Candida colonization, persistent fever despite antibiotics. Micafungin preferred empirically (broader Candida coverage). Step down to fluconazole if C. albicans confirmed susceptible. |
| Known prior MDR organism (prior ESBL/CRE culture, MDR colonization, or local antibiogram > 10โ20% ESBL) | Meropenem (Merrem) 1g IV q8h (ESBL, AmpC, Pseudomonas) + Vancomycin (Vancocin) (MRSA) | Reserve carbapenems for documented resistant organisms or high institutional ESBL prevalence. Add micafungin if Candida risk (TPN, lines, abdominal surgery). |
๐ Vancomycin monitoring (2020 ASHP/IDSA): Target AUC/MIC 400โ600 using Bayesian software or two-level AUC estimation. Old trough-based dosing (15โ20 mcg/mL) caused unnecessary nephrotoxicity. AUC-guided dosing reduces AKI by ~30%.
Anaerobic Coverage (2026 Update)
๐ 2026 Update, Stop reflexively adding anaerobic coverage. New evidence shows that empiric anti-anaerobic agents (pip-tazo, metronidazole, clindamycin) given to critically ill patients without an anaerobic source are associated with increased mortality, C. difficile, VRE colonization, and worse 30-day outcomes, likely from gut microbiome disruption. Chanderraj, 2024
New default empiric for sepsis with no clear source: Vancomycin + Cefepime 2g IV q8h (covers MRSA + Pseudomonas + GNR without anaerobic spectrum).
Add anaerobic coverage (pip-tazo, metronidazole, or carbapenem) ONLY when there is a clear anaerobic source:
- Intra-abdominal, perforation, peritonitis, abscess, cholangitis, diverticulitis, ischemic bowel
- Aspiration pneumonia with clear risk, poor dentition, lung abscess, empyema, witnessed large-volume aspiration. Routine CAP-aspiration does NOT need anaerobes.
- Necrotizing soft tissue infection, gas-forming, polymicrobial, Fournier's
- Female pelvic, PID, tubo-ovarian abscess, septic abortion, postpartum endometritis
- Oropharyngeal / dental / head & neck, Ludwig's angina, deep neck space infection, odontogenic abscess
- Bite wounds, human or animal
If none of the above apply, use Vanc + Cefepime instead of Vanc + Zosyn. This change alone reduces C. diff, AKI, and mortality in mixed-source critical care cohorts.
Vasopressor Guide
| Agent | Dose | Receptor | Role | Avoid |
|---|---|---|---|---|
| Norepinephrine (Levophed) 1ST LINE | 0.01โ3 mcg/kg/min | ฮฑโ>>ฮฒโ | First-line. โ SVR + mild inotropy | - |
| Vasopressin (Pitressin) ADD-ON | 0.03 units/min (fixed, no titration) | V1/V2 | Add vasopressin when NE dose reaches 0.25โ0.5 mcg/kg/min (per SSC 2026). Adding vasopressin early allows NE dose reduction (NE-sparing effect). May reduce AKI (V2-mediated water reabsorption). Non-catecholamine โ works even in catecholamine-resistant shock (acidosis, downregulated adrenergic receptors). VASST 2008 SSC 2026 | Cardiac ischemia (coronary vasospasm), mesenteric ischemia at high doses, hyponatremia (V2 effect -monitor Naโบ) |
| Epinephrine (Adrenalin) 2ND LINE | 0.01โ0.5 mcg/kg/min | ฮฑโ, ฮฒโ, ฮฒโ | Refractory shock. Adds inotropy. | Falsely elevates lactate (ฮฒโ effect) |
| Phenylephrine (Neo-Synephrine) | 0.5โ6 mcg/kg/min | ฮฑโ pure | If tachyarrhythmia limits NE | Low CO states (pure vasoconstriction) |
| Dobutamine (Dobutrex) | 2โ20 mcg/kg/min | ฮฒโ>ฮฒโ | Low CO despite adequate MAP | Without vasopressor if MAP < 65 |
| Dopamine (Intropin) AVOID | - | D1, ฮฒโ, ฮฑโ | Avoid in sepsis -more arrhythmias, higher mortality SOAP II, 2010 | Avoid |
Adjuncts
| Drug | Indication | Dose | Evidence |
|---|---|---|---|
| Hydrocortisone (Solu-Cortef) | Septic shock with ongoing vasopressor requirement (SSC 2021/2026 -conditional) | 200 mg/day IV (50 mg q6h or continuous) | ADRENAL 2018 -faster shock reversal; APROCCHSS 2018 -mortality benefit with hydrocort + fludrocort |
| Drotrecogin alfa | - | Withdrawn from market | PROWESS-SHOCK 2012 -no benefit |
๐ On Rounds
De-Escalation Clinical Scenarios
De-escalation is mandatory. Broad-spectrum empiric antibiotics carry real harms: C. difficile, fungal infections, nephrotoxicity, resistance selection. Once cultures return, narrow to the narrowest agent that covers the identified organism. Stop antibiotics at 5โ7 days if source controlled and patient improving. Use procalcitonin to guide duration.
| Clinical Scenario | Why This Empiric | Culture Result | De-Escalate To | Duration |
|---|---|---|---|---|
| Sepsis, no clear source most common starting point | Vanc + Cefepime, covers MRSA + Pseudomonas + GNR. No anaerobic source โ no Zosyn (2026). | Blood cx: MSSA | Stop both. โ Cefazolin 2g IV q8h | Bacteremia: 2โ4 weeks |
| Sepsis, no clear source | Vanc + Cefepime, broadest non-anaerobic empiric | Blood cx: MRSA | Stop cefepime. Continue Vancomycin (AUC-guided) | Min 2 weeks, longer if endocarditis |
| Fever + tachycardia (unclear source) very common, often turns out to be SIRS, not sepsis | Vanc + Cefepime, empiric for possible sepsis without anaerobic source | All cx negative at 48h. PCT < 0.25. Improving. | Stop all antibiotics. Consider non-infectious SIRS? | Stop if no infection identified |
| CAP (standard) Pulmonary source = ~40โ50% of sepsis | Ceftriaxone + Azithro, standard CAP: typicals + atypicals | Legionella urinary antigen positive | Stop ceftriaxone. Continue Azithromycin 500mg IV/PO daily alone (or levofloxacin) | 5 days (azithro) or 7 days (levo) |
| Severe CAP + sepsis | Vanc + Zosyn, severity warranted broad coverage beyond standard CAP regimen | Sputum: S. pneumoniae (pan-sensitive). MRSA swab neg. | Stop vanc (NPV > 95%). Zosyn โ Ceftriaxone 1g IV daily โ PO amoxicillin when afebrile | 5 days total (PCT-guided) |
| Urosepsis GU source = ~20โ25% of sepsis | Vanc + Cefepime, empiric until source confirmed (no anaerobes, urinary tract is not an anaerobic source) | Urine cx: E. coli (pansensitive) | Stop both. โ Ceftriaxone 1g IV daily โ PO cipro or TMP-SMX | UTI: 5โ7 days. Pyelo: 7โ10 days |
| Pyelonephritis + sepsis | Ceftriaxone 1g IV daily, first-line for community-acquired urosepsis (GNR coverage) | Urine: E. coli (susceptible to cipro + TMP-SMX) | IV โ PO ciprofloxacin 500mg BID or TMP-SMX DS BID when afebrile + tolerating PO | 7 days total |
| Perforated appendicitis (post-op) Abdominal source = ~15โ20% of sepsis | Zosyn 3.375g IV q6h, GNR + anaerobe coverage for abdominal source | Intra-abdominal: E. coli + Bacteroides (susceptible) | Continue Zosyn โ PO amox-clav 875/125 q12h when tolerating PO | 4 days post source control STOP-IT, 2015 |
| SBP (cirrhosis + ascites) | Ceftriaxone 2g IV daily, SBP is monomicrobial GNR (E. coli, Klebsiella). Not polymicrobial โ does NOT need anaerobic coverage. If healthcare-associated SBP or recent abx: cefepime or meropenem. | Ascitic fluid cx: E. coli. Susceptible to ceftriaxone. | Continue ceftriaxone. | 5 days. Repeat paracentesis at 48h, PMN should drop > 25%. |
| Cellulitis (admitted, severe) Skin/soft tissue source = ~5โ10% of sepsis | Vanc + Cefepime, MRSA + GNR. Non-necrotizing cellulitis is NOT an anaerobic infection, skip Zosyn (2026). | Blood cx negative at 48h. No abscess. Non-purulent. | Stop both. โ PO cephalexin 500mg q6h. If purulent: TMP-SMX DS BID | 5 days |
| HAP/VAP | Vanc + Cefepime, hospital-acquired = Pseudomonas + MRSA risk. Cefepime preferred over Zosyn (2026), pneumonia is not an anaerobic source unless aspiration with abscess/empyema. | Sputum: Pseudomonas aeruginosa (susceptible to cefepime) | Stop vanc. Continue Cefepime 2g IV q8h | 7 days for HAP/VAP |
| Line sepsis (suspected CLABSI) | Vanc + Cefepime, MRSA + GNR coverage for line infection (line is not an anaerobic source) | Blood cx: Coag-negative Staph (1 of 2 bottles) | Likely contaminant. 1 bottle + improving + no hardware โ stop vanc. If 2/2 bottles or prosthetic โ treat. | Contaminant: stop. True: 5โ7 days (no hardware) or 4โ6 wks (prosthetic) |
| Neutropenic fever | Vanc + Cefepime, cefepime = anti-pseudomonal monotherapy for febrile neutropenia; vanc if line infection suspected | Blood cx: Enterococcus faecalis (ampicillin-susceptible) | Stop both. โ Ampicillin 2g IV q4h | 2โ4 weeks (rule out endocarditis with TTE/TEE) |
| Neutropenic fever (no source found) | Vanc + Cefepime, standard febrile neutropenia regimen | All cx negative at 72h. ANC recovering (> 500). | Stop antibiotics when afebrile ร 48h + ANC > 500 ร 2 days | Stop with ANC recovery. |
| Sepsis + prior ESBL on antibiogram uncommon, modifier based on prior cultures | Meropenem + Vanc, known ESBL colonization requires carbapenem empirically | Blood cx: ESBL E. coli | Stop vanc. Continue meropenem. IV โ PO TMP-SMX if susceptible for step-down | 7โ14 days (source-dependent) |
| Sepsis + TPN/central line + prior abx | Vanc + Cefepime + Micafungin, Candida risk factors (TPN, lines, broad abx). No anaerobic source โ cefepime, not Zosyn. | Blood cx: Candida albicans (fluconazole-susceptible) | Stop vanc + cefepime. Micafungin โ Fluconazole 400mg IV/PO daily. Remove all central lines. | 14 days from first negative blood cx |
| VAP + prior meropenem use | Meropenem + Vanc, prior carbapenem use selects for resistant organisms | Sputum: Stenotrophomonas maltophilia | Stop meropenem (intrinsically resistant). โ TMP-SMX 15mg/kg/day IV divided q6-8h | 10โ14 days. Meropenem selects for Steno. |
| Necrotizing fasciitis rare, surgical emergency | Vanc + Zosyn, broadest empiric for polymicrobial soft tissue infection | Wound cx: Group A Strep | Stop both. โ Penicillin G 4MU IV q4h + Clindamycin 900mg IV q8h (toxin suppression) | Until debridement complete + clinical improvement |
The narrowest effective antibiotic is the best antibiotic.
Pimp Questions
What is the Sepsis-3 definition of sepsis vs septic shock?
Sepsis: life-threatening organ dysfunction from dysregulated host response to infection, operationally: suspected infection + SOFA increase โฅ 2. Septic shock: sepsis requiring vasopressors for MAP โฅ 65 plus lactate > 2 despite adequate fluids. Both criteria must be met, a patient on pressors with normal lactate is sepsis, not septic shock. Mortality > 40%.
What does lactate actually measure, and what is "cryptic shock"?
Lactate reflects tissue hypoperfusion + aerobic glycolysis from stress, it is NOT just "anaerobic metabolism." Lactate โฅ 2 with normal BP = "cryptic shock", these patients have the same mortality as overt shock if untreated. Lactate โฅ 4 = mandatory resuscitation regardless of MAP. Target lactate clearance โฅ 10% per 2 hours ANDROMEDA-SHOCK, 2019.
Walk me through the sepsis bundle. What goes first and what's the time target?
Within 1 hour (septic shock) or 3 hours (sepsis without shock) per SSC 2026: (1) Lactate, measured immediately, repeat in 2โ4h. (2) Blood cultures ร 2, from 2 separate sites before abx, but never delay abx for cultures. (3) Broad-spectrum antibiotics, every hour of delay โ +7% mortality. (4) 30 mL/kg balanced crystalloid (LR over NS) if hypotensive or lactate โฅ 4
Why is LR preferred over normal saline? When would you use NS instead?
NS causes hyperchloremic metabolic acidosis โ renal afferent vasoconstriction โ โ GFR โ AKI. SMART, 2018: LR/PlasmaLyte reduced death + new renal failure vs NS. Use NS only for: (1) hyponatremia, (2) TBI (LR is slightly hypotonic, risk of cerebral edema), (3) running with blood products (LR has calcium โ clots with citrated blood). SSC 2026 strengthened this to "suggest balanced crystalloids over NS."
Your septic patient's MAP is 58 after 2L of crystalloid. What do you do?
Start norepinephrine now, don't keep bolusing. CENSER, 2019: early NE initiation alongside fluids improved shock control. Start peripherally via large-bore IV above antecubital fossa if no central line, SSC 2026 explicitly endorses this. Fluid overload kills: > 5โ6L in 24h independently increases mortality, worsens ARDS, delays extubation. Pressors are not a failure, they're the next step.
Why is norepinephrine first-line? What receptor profile makes it ideal for sepsis?
NE is a potent ฮฑโ agonist (vasoconstriction โ raises MAP) with mild ฮฒโ (maintains cardiac output without tachycardia). SOAP II, 2010: dopamine caused 2ร more arrhythmias (24% vs 12%) with trend toward higher mortality. Dopamine's dose-dependent receptor effects (D1โฮฒโโฮฑโ) are unpredictable. Phenylephrine (pure ฮฑโ) is avoided because it drops CO. Only use pressor-dose epi if also needing inotropic support.
Patient on NE 0.3, MAP still 60. Walk through your vasopressor escalation.
Step 1: Add vasopressin 0.03 units/min (fixed dose, no titration), works via V1 receptors, catecholamine-independent VASST, 2008. Step 2: Hydrocortisone 50 mg IV q6h for ongoing vasopressor-dependent shock ADRENAL, 2018. Step 3: Stop and reassess, (a) source control adequate? (b) bedside echo: is this actually cardiogenic or mixed shock? (c) missed adrenal crisis, hemorrhage, or obstructive cause? More pressors without a diagnosis is not a plan.
When do you give stress-dose steroids? What trial data supports it?
Hydrocortisone 200 mg/day (50 mg IV q6h) for septic shock with ongoing vasopressor requirement (SSC 2021 reversed the 2016 stance; maintained in 2026). ADRENAL, 2018: no mortality benefit but faster shock reversal. APROCCHSS, 2018: hydrocortisone + fludrocortisone DID reduce 90-day mortality. Don't do a cosyntropin stim test first, it doesn't predict who benefits. Taper over 3โ5 days after pressors off.
How do you assess fluid responsiveness in a septic patient?
Only ~50% of septic patients are fluid-responsive, giving fluid to non-responders causes harm. Best bedside tests: (1) Passive leg raise (PLR), raise legs to 45ยฐ, if CO or pulse pressure increases > 10%, patient is preload-responsive. (2) Pulse pressure variation (PPV) > 13% on arterial line (only valid if mechanically ventilated, Vt โฅ 8, sinus rhythm)
What empiric antibiotics do you choose for undifferentiated septic shock?
Vancomycin + cefepime 2g IV q8h is the new 2026 default, covers MRSA + Pseudomonas + GNR without unnecessary anaerobic spectrum. Chanderraj, 2024 showed empiric anti-anaerobic agents (Zosyn, metronidazole, clinda) given without an anaerobic source โ mortality, C. diff, and VRE. Add Zosyn or metronidazole ONLY for clear anaerobic sources: intra-abdominal, aspiration w/ abscess/empyema, nec fasc, pelvic, or bite wounds. MDR / prior ESBL โ meropenem 1g q8h. Add micafungin if Candida risk. SSC 2026: 1h for shock, 3h for sepsis without shock.
When should you intubate a septic patient? What are the risks?
Intubate for airway protection (GCS โค 8), refractory hypoxemia (SpOโ < 90% on high-flow), or respiratory fatigue (rising RR, accessory muscle use, rising lactate from breathing work). Danger: intubation in septic shock can cause cardiovascular collapse, induction agents drop SVR + preload, positive pressure ventilation drops venous return.
What is the difference between warm shock and cold shock? How does it change management?
Warm shock (early/classic): high CO + low SVR โ warm extremities, bounding pulses, wide pulse pressure, flash CRT. Treat with vasopressors alone. Cold shock: low CO + high SVR โ mottled/cool extremities, weak pulses, narrow PP, delayed CRT, low ScvOโ. Treat with vasopressors + dobutamine (start 2.5 mcg/kg/min, max 20). Septic cardiomyopathy occurs in ~40%, biventricular, reversible in 7โ10 days. Diagnose with bedside echo (poor EF, dilated LV).
How do you use procalcitonin to guide antibiotic duration?
Check PCT at baseline then q48โ72h. Stop antibiotics when: PCT < 0.25 OR โฅ 80% decline from peak PRORATA, 2010: safely reduced abx duration by 2.7 days. False positives (elevated without infection): post-surgery, burns, cardiac arrest, pancreatitis, trauma. False negatives (low despite infection): localized/walled-off infections (abscess, empyema), early infection (< 6h).
What is source control and when does delayed source control kill?
Source control = physically removing the nidus of infection. Antibiotics alone cannot sterilize undrained abscesses, necrotic tissue, or infected hardware. Time-critical sources: (1) necrotizing fasciitis โ OR within hours, (2) bowel perforation โ surgical repair, (3) cholangitis with stone โ ERCP, (4) obstructed pyelonephritis โ nephrostomy or stent, (5) infected central line โ pull it. Target source control within 6โ12 hours.
Patient cleared lactate, on NE 0.06 + vasopressin. How do you wean?
Wean NE first, vasopressin last. Reduce NE by 0.02โ0.05 mcg/kg/min q15โ30 min while monitoring MAP. Once NE is off โ wean vasopressin by 0.01 units/min q30 min. Why vasopressin last? It provides catecholamine-independent vasoconstriction, stopping it first causes rebound hypotension requiring NE re-escalation. Taper hydrocortisone over 3โ5 days after all pressors are off, abrupt discontinuation risks adrenal crisis.
An elderly patient presents with AMS and hypotension but no fever. Can this be sepsis?
Absolutely, and this is the most commonly missed presentation. Elderly, immunocompromised (transplant, chemo), and patients on chronic steroids may present with no fever, minimal leukocytosis, and normal HR. Hypothermia (temp < 36ยฐC) and leukopenia in sepsis are very bad prognostic signs, worse outcomes than febrile patients. Think sepsis in any elderly patient with unexplained AMS + hypotension, even with a normal WBC and no fever.
What role does albumin play in sepsis resuscitation?
SSC 2026 reversed course: now suggests crystalloids alone over crystalloids + albumin for initial resuscitation. This flips the 2021 recommendation. Exception: albumin may still be appropriate after large crystalloid volumes or in cirrhosis. SAFE, 2004: no overall benefit vs saline. ALBIOS, 2014: targeting albumin โฅ 3 g/dL did not improve 28-day mortality. Bottom line: don't reflexively add albumin to your resuscitation -crystalloids alone are sufficient for most patients.
How much fluid is too much? When does fluid resuscitation become harmful?
There is no safe "magic number", assess after every bolus. After the initial 30 mL/kg, further fluid should be given only if the patient demonstrates fluid responsiveness (PLR, PPV, or CO response to bolus). Signs of fluid overload: rising FiOโ requirements, new crackles, worsening P/F ratio, rising CVP with no MAP improvement, positive fluid balance > 5โ6L. FACTT, 2006: conservative fluid strategy shortened ventilator days in ARDS.
Clinical Examples
๐ Case 1, Urosepsis with Cryptic Shock
Patient: 78 y/o F with DM2 and CKD3, presents with confusion, dysuria, and fever 39.2ยฐC for 1 day.
Key findings: HR 112, BP 108/68, RR 24. Lactate 4.2, WBC 18.4K, Cr 2.8 (baseline 1.6), UA positive for nitrites and leukocyte esterase.
Management:
- Blood cultures x2 drawn, then ceftriaxone 1g IV within 1 hour SSC, 2026
- 30 mL/kg LR bolus (lactate โฅ 4 = mandatory resuscitation)
- Repeat lactate at 2h, clearance โฅ 10% is the target
- CT abdomen to rule out renal abscess or obstruction
Teaching point: Cryptic shock, lactate โฅ 4 with normal blood pressure. This patient meets septic shock criteria even though MAP is adequate. Do not be falsely reassured by a normal BP when lactate is elevated.
๐ Case 2, Refractory Septic Shock with Vasopressor Escalation
Patient: 62 y/o M with COPD, presents with productive cough and fevers. CXR shows RLL consolidation. MAP 52 after 2L LR.
Key findings: HR 128, RR 32, SpOโ 88% on 6L NC. Lactate 6.8, WBC 22K, procalcitonin 14.5.
Management:
- Norepinephrine via peripheral IV, do not delay for central line CENSER, 2019
- Cefepime 2g IV q8h + vancomycin 25 mg/kg load (pneumonia is not an anaerobic source, SSC 2026 / Chanderraj, 2024 prefers cefepime over Zosyn)
- NE at 0.3, MAP still 58, add vasopressin 0.03 u/min VASST, 2008
- Hydrocortisone 50 mg IV q6h (ongoing vasopressor-dependent shock) ADRENAL, 2018
Antibiotic Stewardship: Day 2, sputum culture grows S. pneumoniae (pan-sensitive). MRSA nasal swab negative (NPV > 95%). De-escalate: stop vancomycin, narrow cefepime โ ceftriaxone 1g IV daily. Check PCT trend, if โฅ 80% decline from peak, target 5-day total course.
Teaching point: Vasopressor escalation: NE first โ vasopressin second (fixed 0.03 u/min) โ hydrocortisone if still requiring high-dose pressors. Wean NE first, vasopressin last. Always reassess antibiotics at 48-72h when cultures finalize.
๐ Case 3, Sepsis with Procalcitonin-Guided De-escalation
Patient: 55 y/o F, admitted with severe CAP and sepsis. Started on cefepime + vancomycin empirically (SSC 2026, pneumonia is not an anaerobic source).
Key findings: Admission PCT 8.2. Blood cultures grow pan-sensitive S. pneumoniae. MRSA nasal swab negative. Day 3: PCT 1.4 (83% decline), afebrile x24h.
Management:
- De-escalate vancomycin (MRSA swab negative, NPV > 95%)
- Narrow cefepime to ceftriaxone (culture-directed for S. pneumoniae)
- PCT โฅ 80% decline, stop antibiotics at day 5 PRORATA, 2010
- Total duration: 5 days (not the traditional 7-14)
Antibiotic Stewardship: Culture-directed narrowing is the goal. MRSA swab negative โ stop vancomycin. Pan-sensitive organism โ narrow to simplest effective agent. PCT-guided stop rule avoids unnecessary antibiotic days, fewer C. diff, less resistance, shorter stay.
Teaching point: Procalcitonin-guided de-escalation safely reduces antibiotic duration by 2-3 days. Stop rule: PCT < 0.25 or โฅ 80% decline from peak. Every unnecessary antibiotic day increases C. diff and resistance risk.
๐ Case 4, Urosepsis in Elderly Patient
Patient: 78F from nursing home, altered mental status, T 39.2ยฐC, HR 112, BP 82/48, WBC 22k. Foley catheter in place. UA: positive nitrites, leukocyte esterase, bacteria.
Key findings: Lactate 4.8 mmol/L โ septic shock.
Management:
- Blood cultures ร 2 + urine culture BEFORE antibiotics
- Cefepime 2g IV within 1 hour (covers Pseudomonas, catheter-associated UTI risk). Add vancomycin if concerned for MRSA bacteremia.
- 30 mL/kg LR bolus. Reassess after each liter.
- Norepinephrine via peripheral IV, don't wait for central line SSC, 2026
Antibiotic Stewardship: Day 2, urine culture grows E. coli (pan-sensitive). Narrow cefepime โ ceftriaxone 1g IV daily. Plan transition to PO ciprofloxacin or TMP-SMX for discharge. Total course: 7-10 days for complicated UTI.
Teaching point: Catheter-associated UTI + septic shock = remove the catheter (source control), cover Pseudomonas empirically, start pressors early, and narrow at 48h when cultures return.
๐ Case 5, Necrotizing Fasciitis
Patient: 55M with diabetes, rapidly spreading erythema on left leg ร 12 hours. Pain out of proportion to exam. Crepitus on palpation. T 39.8ยฐC, HR 125, BP 95/58, WBC 28k, lactate 5.2.
This is a surgical emergency, NOT a medical one.
- Do NOT wait for LRINEC score if clinical suspicion is high. Pain out of proportion + crepitus + sepsis = OR now.
- Vancomycin + pip-tazo + clindamycin (clindamycin inhibits toxin production in Group A Strep)
- Emergent surgical consult โ radical debridement within hours. Every hour of delay โ +7.6% mortality.
- Expect return to OR every 24โ48h for re-exploration until margins are clean.
Antibiotic Stewardship: Post-debridement, wound cultures guide narrowing. If Group A Strep confirmed โ narrow to penicillin G + clindamycin (toxin suppression). If polymicrobial โ maintain broad coverage. Duration guided by clinical response, not a fixed number of days.
Teaching point: Nec fasc is a surgical disease with medical support. The antibiotic that matters most is the scalpel. Call surgery BEFORE imaging.
๐ฃ Sample Presentation
One-Liner
"Mr. Torres is a 72-year-old with T2DM and CKD3 who presented with 3 days of fever, dysuria, and confusion. Vitals: BP 82/50, HR 118, Temp 39.1ยฐC. Lactate 4.8. He met criteria for septic shock from presumed urosepsis."
Key Points to Cover on Rounds
Source: urosepsis (urine GNR on gram stain, cultures pending). Antibiotics: ceftriaxone day 2, started within 40 min of arrival. Lactate trending 4.8โ2.1โ1.4. Hemodynamics: NE weaned from 0.12 to 0.04 mcg/kg/min, MAP 68. UOP 45 mL/hr. Cr 2.1 from baseline 1.4, trending down. Plan: narrow abx when cultures finalize, continue NE wean.
Daily Rounds Checklist
- Cultures finalized? โ Narrow antibiotics today if possible. What day of antibiotics are we on?
- Lactate cleared? โ < 2 on two consecutive measurements = adequate perfusion
- Vasopressor trajectory โ Weaning or escalating? Note exact dose and trend
- UOP adequate? โ Target โฅ 0.5 mL/kg/hr. If oliguric -reassess volume status + pressor dose
- Source controlled? โ Drain placed? Infected line removed? Surgery consulted?
- Procalcitonin trend โ Falling PCT supports antibiotic cessation PRORATA 2010
- Glucose 140โ180 mg/dL? โ Avoid hypoglycemia; tight control not beneficial NICE-SUGAR, 2009
- DVT prophylaxis ordered? Stress ulcer prophylaxis (SUP) indicated? Updated (SCCM/ASHP, 2024): SUP only if coagulopathy (PLT <50K, INR >1.5), shock (on vasopressors), or chronic liver disease. Vent alone is no longer a clear indication. Enteral feeding is protective, if tolerating feeds, SUP is likely unnecessary. Discontinue when risk factors resolve.
- Nutrition started? โ Enteral preferred within 24โ48h if hemodynamically stable
- Sedation/delirium assessment โ CAM-ICU, RASS target, daily SAT/SBT
ICU Monitoring
| Parameter | Frequency | Target / Action |
|---|---|---|
| MAP (arterial line) | Continuous | โฅ 65 mmHg; higher if chronic HTN |
| Urine output | Hourly | โฅ 0.5 mL/kg/hr; oliguria = reassess volume + pressors |
| Lactate | q2h until < 2 ร 2 | Target clearance โฅ 10%/2h |
| Blood glucose | q1โ2h (insulin infusion) | 140โ180 mg/dL; avoid < 70 |
| BMP | q6โ12h initially | Monitor AKI (creatinine), electrolytes, bicarb |
| CBC | Daily | Thrombocytopenia = DIC; trend WBC |
| Cultures | At 48โ72h | De-escalate antibiotics based on growth + sensitivities |
| Procalcitonin | q48โ72h | If falling and < 0.25 โ consider stopping antibiotics PRORATA 2010 |
| Coags (INR, fibrinogen, D-dimer) | Daily if coagulopathy | Fibrinogen < 1.5 + falling = DIC |
| Temperature | Continuous | Hypothermia = worse prognosis than fever |
Organ Support Targets
Renal
AKI develops in 40โ50% of septic shock. Avoid nephrotoxins (NSAIDs, aminoglycosides, contrast if possible). CRRT (continuous renal replacement) preferred over IHD in hemodynamically unstable patients. Initiate CRRT for refractory acidosis, hyperkalemia, or volume overload.
Coagulation / DIC
DIC complicates ~35% of septic shock. Treat with FFP if bleeding + INR > 1.5. Platelet transfusion if < 10k (or < 50k if bleeding). Avoid prophylactic FFP unless procedure planned.
Respiratory
Avoid intubation if possible -try HFNC or NIV for early respiratory compromise. If intubated: lung-protective ventilation (TV 6 mL/kg IBW, Pplat โค 30). Daily SAT + SBT per ABCDEF bundle.
Antibiotic Duration
Standard: 5โ7 days for bacteraemia with good source control. Do not continue antibiotics empirically "just in case." Use procalcitonin trend + clinical response.
Certain infections require longer: endocarditis (4โ6 weeks), osteomyelitis (6 weeks -oral step-down is acceptable OVIVA, 2019), S. aureus bacteraemia (minimum 14 days from first negative culture).
Certain infections require longer: endocarditis (4โ6 weeks), osteomyelitis (6 weeks -oral step-down is acceptable OVIVA, 2019), S. aureus bacteraemia (minimum 14 days from first negative culture).
โก Summary
Summary
Definition
Organ dysfunction (SOFA โฅ 2) from infection. Shock = vasopressors + lactate > 2 despite adequate IVF.
1-Hour Bundle
Lactate โ blood cultures ร 2 โ broad-spectrum abx โ 30 mL/kg IVF โ vasopressors if MAP < 65
Antibiotics
Vanc + Cefepime default (2026, no anaerobic source โ no Zosyn). Add Zosyn/metronidazole only if intra-abdominal, aspiration w/ abscess, nec fasc, pelvic, or bite wound. Meropenem if MDR. Narrow at 48โ72h.
Vasopressors
NE first-line (peripheral start OK per SSC 2026). Add vasopressin 0.03 u/min when NE 0.25โ0.5. Hydrocortisone 200 mg/day for ongoing vasopressor-dependent shock. Dobutamine only for low CO.
Source Control
Find it. Drain it. Remove the line. Consult surgery. Equal importance to antibiotics. Target < 6โ12h.
Mortality Hack
Every hour antibiotic delay in septic shock โ +7% mortality. Do not wait for cultures. Culture then treat.
Fluid
LR or PlasmaLyte over NS. 30 mL/kg initial. Stop if no response. Fluid overload kills. Check lactate q2h.
De-escalation
Narrow antibiotics at 48โ72h. Use procalcitonin. Stop at 5โ7 days if improving. Wean vasopressors by MAP response.
๐ One Pager
ICU ยท One Pager
Sepsis & Septic Shock
Every hour of antibiotic delay = ~7% more mortality. Cultures โ antibiotics โ fluids โ pressors โ source control. Do not delay for imaging.
๐ฌ Sepsis-3 Definitions
- Sepsis: SOFA โฅ 2 + suspected infection
- Septic shock: Vasopressors + lactate > 2 despite IVF
- qSOFA: AMS + RR โฅ 22 + SBP โค 100 (โฅ 2 = high risk, screen only)
- SIRS: โฅ 2 of temp >38/<36, HR >90, RR >20, WBC >12k/<4k (historical, high sensitivity triage)
- Lactate โฅ 4 = cryptic shock even if BP normal
๐ฆ Common Sources MOST โ LEAST
- ๐ซ Pulmonary ~40โ50% (pneumonia)
- ๐ฟ GU ~20โ25% (urosepsis)
- ๐ซ Intra-abdominal ~15โ20%
- ๐ฉน Skin/soft tissue ~5โ10%
- ๐ Line / device ~5%
- ๐ง CNS / endocarditis < 5%
- โ No source identified ~10โ15%
โฑ๏ธ Sepsis Bundle SSC 2026
1
Lactate -measure now, repeat if > 2 in 2h. Target clearance โฅ 10%.
2
Blood cultures ร 2 -before antibiotics. UA + urine Cx. Don't delay abx > 45 min.
3
Antibiotics: Vanc + Cefepime default (2026, no anaerobic source โ no Zosyn). Add Zosyn/metronidazole only for intra-abdominal, aspiration w/ abscess, nec fasc, pelvic, or bite wound. Meropenem if prior ESBL/MDR. 1h for septic shock, 3h for sepsis without shock.
4
30 mL/kg LR/PlasmaLyte if MAP < 65 or lactate โฅ 4. Stop if no response. SMART 2018
5
Vasopressors: NE first-line if MAP < 65 despite fluids. SOAP II, 2010
6
Source control: Drain abscess, remove line, decompress biliary. Target < 12h.
๐ Vasopressors
Norepinephrine1st ยท 0.01โ3 mcg/kg/min
Vasopressin0.03 u/min ยท add-on
Hydrocortisone200 mg/d ยท ongoing pressor requirement
EpinephrineRefractory
DobutamineLow CO, MAP ok
๐ Monitoring Targets
MAPโฅ 65 mmHg
UOPโฅ 0.5 mL/kg/hr
LactateClear โฅ 10%/2h
Glucose140โ180 mg/dL
ScvOโโฅ 70%
โ ๏ธ Pitfalls
- Delaying antibiotics for cultures
- Using dopamine SOAP II, 2010
- NS over balanced crystalloids
- No source control
- Broad abx never narrowed
- Missing hypothermia = bad sign
Rounds ยท ICU
SSC 2026 ยท Sepsis-3 2016 ยท SOAP II 2010 ยท SMART 2018 ยท CLOVERS 2023